Optimal treatment strategy of mineralocorticoid receptor antagonists for primary aldosteronism

Optimal treatment strategy of mineralocorticoid receptor antagonists for primary aldosteronism - Optimal treatment strategy of mineralocorticoid receptor antagonists for primary aldosteronism

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030932

Enrollment

Registered

2018-01-23

Start date

2018-02-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary aldosteronism

Interventions

Increase the dose of mineralocorticoid receptor antagonists (MRA) until serum K value reach to normal upper limit (serum K level 4.6-5.0 mEq/L) during 6 months visit (every 4-8 weeks). Basically not c

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients visiting our hospital with primary aldosteronism who agreed to participate in this study. Patients whoes systolic blood pressure is control under 200mmHg and diastolic blood pressure under 120mmHg.

Exclusion criteria

Exclusion criteria: Patients who did not agree to this study, receiving sex hormone therapy, having heart diseases (NYHA 3 degree or higher), liver dysfunction (AST/ALT over 100IU/mL or T-Bil over 2.0mg/dL), renal dysfunction (Cr over 2.0mg/dL), serious diseases such as malignant diseases and judged inappropriate.

Design outcomes

Primary

Measure	Time frame
Blood pressure Urinary albumin	—

Secondary

Measure	Time frame
QOL eGFR	—

Countries

Japan

Contacts

Public ContactAya Saiki

Osaka University Graduate School of Medicine Department of Metabolic Medicine

saiki-a@endmet.med.osaka-u.ac.jp06-6879-3732

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026